Skip to main content
OpenTrials

Clinical trial condition

Thoracic Neoplasms

Explore clinical trials studying Thoracic Neoplasms. Study availability and eligibility vary by location and protocol.

8,059 public trials 1,846 recruiting studies
Refine in advanced search Browse all conditions

Thoracic Neoplasms trial results

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Research Site Anchorage, Alaska, United States
  • Research Site Los Angeles, California, United States
  • Research Site Orange, California, United States
  • Research Site Grand Junction, Colorado, United States
View all 139 locations
View Trial Details
Active, not recruiting

Screening for High Frequency Malignant Disease

NCT05117840

Conditions
Lung Cancer, Lung Diseases, Lung Neoplasms, +5 more
Locations
  • University of Alabama Birmingham Lung Health Center Birmingham, Alabama, United States
  • Highlands Oncology Group PA Fayetteville, Arkansas, United States
  • Pacific Cancer Medical Center Anaheim, California, United States
  • Providence St. Joseph Hospital Eureka Cancer Program Eureka, California, United States
View all 143 locations
View Trial Details
Active, not recruiting

Study of AZD2811 + Durvalumab in ES-SCLC

NCT04745689

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more
Locations
  • Research Site Grand Rapids, Michigan, United States
  • Research Site Bydgoszcz, Poland
  • Research Site Olsztyn, Poland
  • Research Site Poznan, Poland
View Trial Details
Active, not recruiting

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

NCT05047250

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Beijing Tiantan Hospital,Capital Medical University Beijing, China
  • Xuanwu Hospital, Capital Medical University Beijing, China
  • Beijing Chest Hospital Beijing, China
  • The Third Xiangya Hospital Of Central South University Changsha, China
View all 18 locations
View Trial Details
Active, not recruiting

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

NCT05460273

Conditions
Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +13 more
Locations
  • Research Site Beijing, China
  • Research Site Beijing, China
  • Research Site Beijing, China
  • Research Site Bengbu, China
View all 21 locations
View Trial Details
Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843

Conditions
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Lung Diseases, Lung Neoplasms, +5 more
Locations
  • The Brown University Oncology Group Providence, Rhode Island, United States
  • Novartis Investigative Site Pilar, Buenos Aires, Argentina
  • Novartis Investigative Site Córdoba, Córdoba Province, Argentina
  • Novartis Investigative Site Buenos Aires, Argentina
View all 45 locations
View Trial Details
Active, not recruiting

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT01708954

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Memorial Medical Center Modesto, California, United States
  • Community Hospital of Monterey Peninsula Monterey, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
View all 356 locations
View Trial Details
Active, not recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Research Site Beverly Hills, California, United States
  • Research Site La Jolla, California, United States
  • Research Site Los Alamitos, California, United States
  • Research Site Los Angeles, California, United States
View all 47 locations
View Trial Details
Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

NCT02193282

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Southern Cancer Center PC-Daphne Daphne, Alabama, United States
  • Southern Cancer Center PC-Mobile Mobile, Alabama, United States
  • Southern Cancer Center PC-Providence Mobile, Alabama, United States
View all 1407 locations
View Trial Details

Related conditions